Radiopharmaceuticals are used to produce images of organs or tissues of interest, a process that is called scintigraphy. While, contrast media is used in imaging techniques to enhance the differences between body tissues on images. It is a substance used to increase the contrast of structures/fluids within the body in medical imaging.
Market Dynamics:
Increase in prevalence of cardiovascular diseases, rise in burden of cancer, increasing number of diagnostic centres, increasing demand for image-guided procedures and diagnostics, and increase in demand for diagnostic radiopharmaceuticals and contrast media, are major factors expected to propel growth of the global diagnostic radiopharmaceuticals and contrast media market.
For instance, in October 2022, Duchem Bio announced the launched of FACBC, the world’s first radiopharmaceutical used when diagnosing prostate cancer patients, in Korea. The drug, developed by Nihon Medi Physics, a Japanese pharmaceutical company, is used when conducting positron emission tomography (PET) in patients suspected of having prostate cancer recurrence due to an increase in the prostate-specific antigen (PSA) in the blood after prostate cancer treatment.
Key features of the study:
- This report provides in-depth analysis of the global diagnostic radiopharmaceuticals and contrast media market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global diagnostic radiopharmaceuticals and contrast media market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Siemens Healthineers, Nordion Inc., Lantheus Holdings Inc., Guerbet Group, GE Healthcare, Curium, Bracco Imaging SpA, Bayer AG, Cardinal Health Inc., and NTP Radioisotopes SOC Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global diagnostic radiopharmaceuticals and contrast media market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diagnostic radiopharmaceuticals and contrast media market.
Detailed Segmentation:
- Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Radiopharmaceuticals
- By Type of Imaging Modality:
- By Application
- Diagnostic application
- Therapeutic application
- Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Contrast Media
- By Procedure
- X-Ray/Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Ultrasound
- By Application
- Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Company Profiles:
- Siemens Healthineers
- Nordion Inc.
- Lantheus Holdings Inc.
- Guerbet Group
- GE Healthcare
- Curium
- Bracco Imaging SpA
- Bayer AG
- Cardinal Health Inc.
- NTP Radioisotopes SOC Ltd.
